WASHINGTON (AP) -- Federal health officials say the maker of Lunesta must lower the starting dose of its sleeping aid drug due to risks of morning drowsiness, which can interfere with driving ability and lead to injury.
The Food and Drug Administration is taking action based on a study that found Lunesta at recommended doses can cause problems with driving, memory and coordination up to 11 hours after first the drug is taken. Patients are often unaware that they are still drowsy.
Lunesta manufacturer Sunovion Pharmaceuticals will lower the starting dose of the tablet to 1 milligram from 2 milligrams. Patients can increase their dose, but should remember that higher doses are more likely to cause impairment the next day, according to the FDA.
Drowsiness is a side effect for all anti-insomnia drugs.
To comment, the following rules must be followed:
Comments may be monitored for inappropriate content, but the station is under no legal obligation to do so.
If you believe a comment violates the above rules, please use the Flagging Tool to alert a Moderator.
Flagging does not guarantee removal.
Multiple violations may result in account suspension.
Decisions to suspend or unsuspend accounts are made by Station Moderators.
Questions may be sent to firstname.lastname@example.org.
Please provide detailed information.
All comments must adhere to the WSAW.com discussion rules.